Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate the Safety, Tolerability and Immunogenicity of pPJV7630, a Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused by HSV-2

NCT00274300 is registered in ClinicalTrials.gov with PowderMed as lead sponsor.

NCT NCT00274300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00274300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate the Safety, Tolerability and Immunogenicity of pPJV7630, a Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused by HSV-2
Lead sponsor
PowderMed
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2004
Completion date
July 31, 2005
Enrollment
36
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hsv-2